Ipotuba Information

Ipotuba developed CryoNest, a patented passive ultra-cold transport technology designed for high-value, temperature-sensitive pharmaceutical products. CryoNest offers an alternative to conventional dry-ice shipping, combining extended passive cooling with operational simplicity. **Key features:** • Experimentally demonstrated seven-day temperature plateau at approximately −80°C under constant 25°C ambient conditions. • A distinctive thermal profile, beginning below −80°C and followed by gradual warming over several additional days after the plateau. • Dry-ice-free and liquid-nitrogen-free operation during transport. • Orientation-independent design, suitable for integration into conventional courier logistics. • Compact payload configuration, currently accommodating up to six vial positions. **Our focus** We are particularly interested in personalized cancer vaccines, mRNA/LNP medicines, clinical trial materials and other high-value pharmaceutical shipments requiring ultra-cold transportation. CryoNest is being developed for end-to-end pharmaceutical logistics, not merely last-mile delivery. We welcome collaboration with pharmaceutical developers, biotechnology companies, CDMOs and specialized logistics providers to assess real-world transport requirements and qualification opportunities. **Let's discuss your ultra-cold shipping challenges.** www.ipotuba.com